Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30056202HIVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS30056203HIVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS30056204HIVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS30056205HIVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS20000346HPVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS20007372HPVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS20010046HPVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS20057760HPVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS20042374HPVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TVIS20037897HPVENSG00000196277.17protein_codingGRM7NoNo2917B9EGG9
Q14831
TCGA Plot Options
Drug Information
GeneGRM7
DrugBank IDDB00142
Drug NameGlutamic acid
Target IDBE0000834
UniProt IDQ14831
Regulation Type
PubMed IDs17360958
CitationsSuzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H: Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl- 3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.
GroupsApproved; Nutraceutical
Direct ClassificationGlutamic acid and derivatives
SMILESN[C@@H](CCC(O)=O)C(O)=O
PathwaysHistidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling
PharmGKBPA449776
ChEMBLCHEMBL575060